BioSpace News Archive

The main results of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) trial, a National Heart, Lung, and Blood Institute (NHLBI) sponsored trial were presented.

RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida.

Pfizer Canada ULC announced today that Health Canada has accepted for review the New Drug Submission for its bivalent Respiratory Syncytial Virus (RSV) vaccine.

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the world’s smallest, thinnest and most discreet5 glucose sensor.

Evofem Biosciences, Inc., the maker of Phexxi®, announced the appointment of Ivy Zhang as Chief Financial Officer and Secretary, effective April 13, 2023.

Epic Sciences, Inc., a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months.

Pressure BioSciences, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022, provided a business update, and offered guidance for a strong 2023, beginning with record revenue in the 2023 first quarter.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has successfully secured U.S. Medicare and Medicaid reimbursement through various payers.

Harbour BioMed today announced that the results of its phase Ib clinical trial of porustobart (HBM4003) in combination of toripalimab in patients with advanced high-grade neuroendocrine neoplasms.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will present updated data from the Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) at the American Association for Cancer Research (AACR) Annual Meeting 2023.